Prescription Sleep Medications: Types, Risks, and Alternatives

Evidence-based | Last updated June 2025

Prescription sleep medications are among the most prescribed drugs in the world, yet they remain widely misunderstood — both in terms of how they work and their appropriate role in treating insomnia. This guide covers the major classes, their mechanisms and risks, and explains why clinical guidelines now recommend cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment before medications are considered.

Z-Drugs: Zolpidem and Eszopiclone

The "z-drugs" — so named because most begin with the letter Z — include zolpidem (Ambien, Ambien CR), eszopiclone (Lunesta), and zaleplon (Sonata). They were developed in the 1990s as supposedly safer alternatives to benzodiazepines.

Mechanism

Z-drugs are GABA-A receptor positive allosteric modulators, like benzodiazepines, but are more selective for the alpha-1 subunit of the GABA-A receptor, which mediates sedation. This selectivity was expected to reduce some of the dependence, cognitive, and abuse-potential issues of benzodiazepines — but in practice, the differences have been less dramatic than initially hoped.

Effectiveness

Z-drugs do reduce sleep latency (time to fall asleep) by approximately 15-20 minutes compared to placebo in clinical trials, and improve subjective sleep quality. The effects are real but modest. They are more effective for sleep onset than sleep maintenance (staying asleep).

Risks and FDA Warnings

• Parasomnias: Sleepwalking, sleep-driving, sleep-eating, and other complex behaviors performed while technically asleep have been documented with zolpidem specifically. These can occur without memory the following day. The FDA has issued black box warnings on all z-drugs for this risk.
• Dependence and tolerance: Physical and psychological dependence can develop with regular use. Abrupt discontinuation can cause rebound insomnia (worse sleep than before starting) and, with long-term high-dose use, withdrawal symptoms.
• Next-day impairment: Particularly with extended-release formulations and in women (who metabolize zolpidem more slowly), next-day cognitive impairment and driving impairment are documented risks. The FDA lowered the recommended starting dose for women from 10mg to 5mg because of this.
• Cognitive effects: Regular z-drug use is associated with next-day memory impairment and, with long-term use, potential cumulative cognitive effects.

Current guidance: Z-drugs are recommended for short-term use only (typically 2-4 weeks), at the lowest effective dose, and with a plan for discontinuation. They should not be combined with alcohol, opioids, or other CNS depressants.

Benzodiazepines

Traditional benzodiazepines used for sleep include temazepam (Restoril), triazolam (Halcion), flurazepam, and quazepam. They act on the same GABA-A receptor system as z-drugs but are less selective, affecting more receptor subtypes and producing broader CNS depression.

Benzodiazepines have largely fallen out of favor as sleep medications because their dependence potential, abuse potential, and withdrawal syndrome are more severe than z-drugs. They are still used — particularly temazepam — but are generally not first-line and are prescribed for shorter durations than they once were. Long-term benzodiazepine use produces tolerance, requiring dose escalation, and discontinuation can require a slow taper over months to avoid withdrawal symptoms including severe rebound anxiety and insomnia, tremor, and in severe cases seizures.

Orexin Receptor Antagonists: Suvorexant and Lemborexant

Suvorexant (Belsomra) and lemborexant (Dayvigo) represent a fundamentally different approach to sleep pharmacology. Rather than forcing sleep by broadly suppressing CNS activity, they block orexin (hypocretin) receptors. Orexin is a wake-promoting neurotransmitter — blocking its action reduces the "drive to stay awake" rather than imposing sedation. This is sometimes described as promoting sleep by removing the active wakefulness signal, rather than suppressing consciousness.

Advantages

The dependence potential appears lower than z-drugs or benzodiazepines. Rebound insomnia on discontinuation is milder. The mechanism is conceptually closer to natural sleep than broad CNS depression. Lemborexant may have slightly better effects on sleep maintenance (reducing nighttime awakenings) compared to some z-drugs.

Limitations

Some rebound insomnia still occurs on discontinuation. Next-day somnolence can occur, particularly at higher doses. They are significantly more expensive than generic z-drugs. They also carry FDA warnings for sleep-related behaviors, though the evidence suggests these occur less frequently than with zolpidem. Narcolepsy (caused by orexin deficiency) is an absolute contraindication.

Trazodone: Off-Label Use

Trazodone is an antidepressant that, at doses lower than its antidepressant range (25-100mg vs. 150-300mg), is widely used off-label for insomnia. It promotes sleep primarily through antagonism of serotonin 5-HT2A and histamine H1 receptors. It does not cause the same dependence or complex sleep behavior risks as z-drugs and benzodiazepines, making it appealing as a longer-term option when a pharmacological approach is needed.

Trazodone is not FDA-approved for insomnia specifically, and the clinical evidence base is smaller than for approved sleep medications. It is nonetheless commonly prescribed, particularly in the context of depression comorbid with insomnia, or when other sleep medications are contraindicated. Side effects include orthostatic hypotension (blood pressure drop on standing — fall risk particularly in elderly), next-day sedation, and rarely a condition called priapism (prolonged erection) in men.

Melatonin Receptor Agonists: Ramelteon

Ramelteon (Rozerem) is the only FDA-approved sleep medication that is not a controlled substance. It is a melatonin receptor (MT1 and MT2) agonist with higher receptor affinity than melatonin itself. It works by signaling to the circadian clock that it's nighttime — like melatonin, it's a timing signal rather than a sedative.

Ramelteon modestly reduces sleep latency but has little to no effect on sleep maintenance. Its advantages are its exceptional safety profile: no dependence or abuse potential, no parasomnias, no cognitive impairment, and no meaningful drug tolerance. It is the preferred option for older adults, people who cannot take controlled substances, and people with a history of substance use disorder. Its modest effectiveness means it's best suited for people with primary sleep onset difficulties rather than severe insomnia.

Why CBT-I Should Come First

Multiple head-to-head trials have compared CBT-I to sleep medications for chronic insomnia. The consistent finding: CBT-I and sleep medication produce similar short-term improvements in sleep, but CBT-I produces superior long-term outcomes, with benefits that continue to improve after treatment ends. Medications provide benefit only while taken.

CBT-I works by:

• Eliminating maladaptive thoughts and behaviors that perpetuate insomnia (cognitive restructuring)
• Restricting time in bed to consolidate sleep (sleep restriction therapy)
• Using the bed only for sleep and sex (stimulus control)
• Teaching relaxation and arousal reduction techniques
• Rebuilding sleep confidence and reducing sleep anxiety

CBT-I is available from sleep psychologists, trained therapists, and increasingly through validated digital programs (Sleepio, Somryst). It requires more effort than taking a pill but produces lasting change.

Tapering Off Sleep Medications

Discontinuing sleep medications — particularly z-drugs and benzodiazepines — should always be done gradually under medical supervision, not abruptly. Rebound insomnia after stopping is predictable and does not mean the medication was necessary or that the insomnia is incurable. It is the brain adjusting to the absence of GABA enhancement. A CBT-I program run concurrently with a gradual taper produces substantially better outcomes than either a taper or CBT-I alone.